Blog Coverage Viking Presents New Clinical Data on VK2809

Upcoming AWS Coverage on ACADIA Pharmaceuticals Post-Earnings Results

LONDON, UK / ACCESSWIRE / November 16, 2016 / Active Wall St. blog coverage looks at the headline from Viking Therapeutics, Inc. (NASDAQ: VKTX) as the company announced on November 15th, 2016, additional data from its previously completed Phase 1b clinical trial of VK2809 in subjects with mild hypercholesterolemia. Data from an analysis of the study of participants’ atherogenic protein levels demonstrated that subjects experienced statistically significant reductions in lipoprotein(a) [Lp(a)] and apolipoprotein B-100 (apo B). Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

One of Viking Therapeutics’ competitors within the Biotechnology space, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), announced on November 07, 2016, its unaudited financial results for the third quarter ended September 30, 2016. AWS will be initiating a research report on ACADIA Pharma in the coming days.

Today, AWS is promoting its blog coverage on VKTX; touching on ACAD. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/registration-3/?symbol=VKTX

http://www.activewallst.com/registration-3/?symbol=ACAD

VK2809 is a novel, orally available small molecule thyroid receptor agonist that possesses selectivity for liver tissue, as well as the beta receptor subtype, suggesting promising therapeutic potential in this patient population. The company noted that previously reported data demonstrated that treatment with VK2809 leads to rapid reductions in plasma LDL cholesterol (LDL-C) and triglycerides in subjects with mild hypercholesterolemia.

The Study

The study was a randomized, double-blind, placebo-controlled Phase 1b trial designed to evaluate the safety, tolerability and pharmacokinetics of a range of VK2809 doses in 56 subjects with elevated serum cholesterol. Following 14 days of VK2809 treatment, subjects experienced statistically significant placebo-adjusted, least square mean reductions in both Lp(a) and apo B across a range of doses. Reductions in apo B ranged from 20.2% at 5 mg to 39.6% at 40 mg; reductions in Lp(a) ranged from 31.6% at 5 mg (p = 0.12) to 54.9% at 20 mg (p = 0.002).

“These data support the promise of thyroid beta-targeted approaches for the treatment of cardiovascular and other metabolic diseases. We previously reported results showing VK2809’s ability to rapidly reduce plasma LDL-C and triglycerides by up to 41% and 79%, respectively, following just 14 days of treatment,” said Brian Lian, Ph.D., chief executive officer of Viking, “Today’s announcement highlights the added benefit of VK2809 on reducing key proteins associated with elevated cardiovascular risks. The combined benefits from reducing both LDL-C and atherogenic proteins suggest a differentiated therapeutic profile, which may result in improved long-term benefits for patients with lipid or other metabolic abnormalities, including fatty liver disease. We look forward to the results of our on-going Phase 2 trial of VK2809 in patients with hypercholesterolemia and fatty liver disease, which we expect to complete in 1H17.”

Treatment with VK2809 was shown to be safe and well-tolerated at all doses studied in this trial. No serious adverse events were reported and no treatments, or dose-related trends, were observed for abnormal vital signs, electrocardiograms, cardiac rhythm, or physical examination assessments. Consistent with liver-targeted thyroid receptor activation, mild, asymptomatic elevations in liver enzymes and decreased thyroid hormone levels were observed at higher doses. Viking Therapeutics previously announced top-line data from the Phase 1b trial which demonstrated clinically and statistically significant placebo-adjusted reductions in LDL-C ranging from 15.2% at the 5.0 mg dose to 41.2% at the 20 mg dose. Additionally subjects experienced placebo-adjusted reductions in triglycerides ranging from 34.8% at 5.0 mg dose to 78.6% at the 40 mg dose.

About VK2809

VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor in Phase 2 development for the treatment of patients with hypercholesterolemia and fatty liver disease. VK2809 belongs to a family of novel prodrugs which are cleaved in vivo to release potent thyromimetics. Consistent with its liver- and receptor-selective mechanism of action, treatment with VK2809 has also demonstrated rapid reduction of liver fat in animal models of hepatic steatosis. Further animal data have shown that VK2809 has additive cholesterol lowering activity in combination with statins. The company noted that the potential markets for these indications are significant with approximately 33% of adults, or 71 million people, have elevated LDL cholesterol in the U.S.

Stock Performance

At the closing bell, on Tuesday, November 15, 2016, Viking Therapeutics’ stock rose 1.72%, ending the trading session at $1.18. A total volume of 239.96 thousand shares were traded at the end of the day, which was higher than the 3-month average volume of 210.23 thousand shares. In the last month, shares of the company have advanced 6.31%. The stock currently has a market cap of $20.34 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 449135